Moderna, Inc. (MRNA) Revenue by Segment
Moderna revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 30, 2026), Moderna's largest product or service was Covid-19, with $91.00 million or 63% of revenue, down 20.2% from a year earlier. Next: Stand-Ready Manufacturing (21%), Collaboration Arrangement, Including Arrangements With Affiliate (10%) and License and Royalty (2%).
The fastest-growing product or service from a year earlier was Collaboration Arrangement, Including Arrangements With Affiliate (+275.0%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q1 fiscal 2018.
Moderna, Inc.
Revenue breakdown
Fiscal quarters, from company filings
Moderna revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Covid-19 | $91.0M | $345.0M | $971.0M | $114.0M | 63% |
| Stand-Ready Manufacturing | $31.0M | $32.0M | – | $17.0M | 21% |
| Collaboration Arrangement, Including Arrangements With Affiliate | $15.0M | $5.0M | $7.0M | $4.0M | 10% |
| License and Royalty | $3.0M | – | $2.0M | $2.0M | 2% |
| RSV | $3.0M | $7.0M | $2.0M | – | 2% |
| Grant | $2.0M | – | $14.0M | $5.0M | 1% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
Which product or service makes the most money for Moderna?
Covid-19: $91.00 million, or 63% of revenue, in Q2 fiscal 2026.
What are Moderna's main products and services?
By revenue in Q2 fiscal 2026: Covid-19 (63%), Stand-Ready Manufacturing (21%), Collaboration Arrangement, Including Arrangements With Affiliate (10%) and License and Royalty (2%).
